Worldwide revenue from the Plant-Based Vaccines Market was US$ 1.3 Bn in 2021, with the global market estimated to surge ahead at a CAGR of 7.8% to top a valuation of US$ 3 Bn by the end of 2032.
As assessed by Persistence Market Research, viral vaccines accounted for a market value of around US$ 694.7 Mn in 2021. Overall, plant-based vaccine sales accounted for approximately 3.4% of revenue share in the global recombinant vaccines market, which was valued at around US$ 38.1 Bn in 2021.
The global market for plant-based vaccines recorded a historic CAGR of 5.6% in the last 9 years from 2012 to 2021. Vaccines stimulate antibody synthesis in humans and animals, providing immunological protection against a variety of diseases. However, the lack of vaccines for the treatment of deadly diseases has posed concerns and directed global focus toward the development of safer, simpler, and more efficient vaccines.
- The National Institute of Allergy and Infectious Diseases demonstrated for the first time in 1998 that an edible vaccine using the concept of plants as bioreactors might create significant immunogenicity safely.
Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/27961
This technology may give a cheaper alternative for vaccine production because it is easy to handle and does not require elaborate storage, and it is cost-effective and simple to scale up for mass production. Furthermore, plant-based edible vaccines developed in this approach can offer a needleless, simple, and accessible mode of delivery. Tobacco, maize, potatoes, rice, and tomatoes are examples of plants that have been exploited as bioreactors.
Compared to fermentation-based systems, plants have lower infrastructure costs and simpler biomass amplification requirements, which has sparked a lot of interest in their potential as inexpensive biofactories, and, with the suitable crop species, edible vaccines.
As was evident in prior emergency pandemic responses, countries with the ability to manufacture vaccines have had problems in providing them to other nations without compensation. Given the economic implications that the COVID-19 pandemic has already brought, this lack of vaccine distribution is likely to be repeated.
The capacity of plant-based biologics manufacturing facilities to rapidly switch operational pipelines for emergency production runs could be a huge benefit in pandemic crises and should be regarded by government sponsors as an added value of such facilities.
- Creative Biolabs
- Medicago Inc.
- EEA Consulting Engineers
- Kentucky BioProcessing, Inc.
- Baiya Phytopharm
- Protalix Biotherapeutics
Access Full Report@ https://www.persistencemarketresearch.com/checkout/27961
Companies manufacturing plant-based vaccines are concentrating on the development of next-generation plant-based expression technologies that could help reduce the time and expense associated with conventional vaccinations.
While companies in the market are dealing with issues related to 3rd generation vaccine development, they are focusing on the adoption of next-generation technologies that can assist them in developing edible vaccines that are effective against animal- and human-associated illnesses and provide convenience to end users.
- May 2022: According to findings of a Phase III human clinical study, a new plant-based COVID-19 vaccine is around 70% effective against symptomatic diseases brought on by five variants of the coronavirus. Researchers at the Canadian biotechnology company Medicago have developed a vaccine that combines plant-produced coronavirus-like particles (CoVLP) with an adjuvant (ASO3) that improves the efficacy of vaccines.
- In February 2022, Canada approved the use of the first plant-derived COVID-19 vaccine in the world, establishing a new approach to immunizing against the virus. A division of Mitsubishi Chemical Holdings Corp. and Philip Morris International developed this vaccine.
Key Segments of Plant-Based Vaccines Industry Research
- Viral Vaccines
- Bacterial Vaccines
- Zika Virus
- Ebola Virus
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
For more information about this report visit@ https://www.persistencemarketresearch.com/market-research/plantbased-vaccines-market.asp
The Global Effervescent Products market is expected to have a CAGR of 6.50% from USD 41,217.9 Million in 2022 to USD 64,088.9 Million in 2029..
The report on Renal Anemia Treatment further projects significant growth potential with average year-on-year growth rate pegged at 7.5% over the period of 2018-2026..
Over the forecast period 2017-2025, the global market for atrophic scar treatment will reportedly grow at a CAGR of 4.6% along with a healthy revenue. More details.
Check Global Market Study on Triple-Negative Breast Cancer Treatment – explore the rising focus on combination therapies, market expansion, CAGR, revenue, trends and projections.
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353